* Vaxcyte Inc reported a quarterly adjusted loss of 83 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -91 cents. The mean expectation of nine analysts for the quarter was for a loss of $1.13 per share. Wall Street expected results to range from $-1.35 to -88 cents per share.
* Reported revenue was zero; analysts expected zero.
* Vaxcyte Inc's reported EPS for the quarter was a loss of 83 cents.
* The company reported a quarterly loss of $103.12 million.
* Vaxcyte Inc shares had fallen by 6.8% this quarter and gained 69.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1.6% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Vaxcyte Inc is 155.00 This summary was machine generated from LSEG data November 6 at 04:44 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.13 -0.83 Beat
Jun. 30 2024 -0.98 -1.10 Missed
Mar. 31 2024 -1.17 -0.85 Beat
Dec. 31 2023 -1.07 -1.82 Missed
Comments